The radiopharmaceutical company Nuclidium AG has closed a Series B financing of 84 million euros. Lead investors are Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners und Neva SGR (Intesa Sanpaolo Group). The proceeds will be used to fund the further clinical development of the company's theranostic pipeline and the expansion of its global manufacturing and production network for copper-based radiopharmaceuticals.
Nuclidium AG, a Swiss clinical-stage radiopharmaceutical company with a subsidiary in Munich developing a proprietary copper-based theranostic platform, has raised 84 million euro in a Series B financing round. The financing round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Eurazeo, Vives Partners, NRW.BANK and HighLight Capital, as well as existing investors.
The proceeds will be used to advance the clinical development of Nuclidium's copper-61/copper-67 (61Cu/67Cu) theranostic pipeline in various oncology indications. In parallel, the company will further expand its production and manufacturing capabilities through a global manufacturing network for diagnostics and therapeutics, grow its international team and strengthen strategic collaborations with hospitals and academic centers, initially in Europe and North America.
NUCLIDIUM's differentiated platform combines tumor-targeting molecules with copper isotopes - copper-61 for diagnostics and copper-67 for therapeutics - to overcome the current limitations of radiotheranostics, such as suboptimal clinical efficacy and manufacturing complexity.
Diagnostic results from initial clinical trials in these indications show better lesion detection and tumor-to-background ratios compared to clinically approved tracers. Initial data was recently presented at SNMMI 2025 by Dr. Gary Ulaner, MD, PhD, demonstrating a favorable safety profile and potentially improved imaging performance of 61Cu-NuriPro™ compared to current PET imaging standards, suggesting great clinical potential and broader potential for the 61Cu/67Cu theranostic pairing.
Early therapeutic data from the two lead agents NuriPro™ and TraceNET™ show a strong tumor-to-background ratio in metastatic prostate cancer and neuroendocrine tumors including breast cancer.